Use of Precision Medicine Molecular Profiling of Baseline Tumor Specimen May Not Benefit Outcomes in Children With Relapsed or Refractory Pediatric Sarcomas
Date
2017-03
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Wiley
Abstract
Given the poor prognosis of pediatric patients with relapsed or refractory sarcomas, discovery and implementation of innovative approaches and tools to guide therapy are urgent needs. This retrospective pilot study evaluated the impact of relapse and refractory therapies aligned with molecular characterization of biopsies collected at the time of primary diagnosis.
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Carter, J., Cheng, L., Zucker, J., Marshall, M., Pollok, K., Murray, M., … Renbarger, J. (2017). Use of Precision Medicine Molecular Profiling of Baseline Tumor Specimen May Not Benefit Outcomes in Children With Relapsed or Refractory Pediatric Sarcomas. Clinical Pharmacology and Therapeutics, 101(3), 328–330. https://doi.org/10.1002/cpt.599
ISSN
0009-9236
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Clinical pharmacology and therapeutics
Rights
Publisher Policy
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Author's manuscript